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CHAPTER 3 
 
 ATTEMPTS TOWARDS CRYSTALLIZATION OF 
DEN-2 PROTEASE COMPLEX 
 
 
 
Protein Crystallization Attempts                                                                                                      Chapter 3 
 35 
3.1 Protein crystallization of DEN-2 NS2B-NS3pro 
 
 Until very recently, attempts to crystallize the protease complex that is 
responsible for viral replication of DEN-2 by various groups have not been successful. 
Crystallization of DEN-2 protease complex was inevitable as structural information is 
greatly required to enable us to perform structural studies involving compounds with 
inhibitory activities in our effort to search for a therapeutic agent against dengue 
infections. Understanding the structural interactions between protease and ligand will 
provide important information for inhibitory activity studies which may lead to a design 
of candidate as anti-dengue drug. 
 
 This chapter discusses the experiments performed in attempts to crystallize the 
DEN-2 NS2B-NS3pro complex. The data and information obtained from a crystal 
structure will be used as input for the subsequent parts of the project involving 
computational modelling studies. Unfortunately, our attempts did not produce any 
protein crystals. The reasons behind these unsuccessful attempts are established and will 
be discussed in this chapter.    
 
3.2 Materials and methods 
3.2.1 Materials 
3.2.1.1 Materials and instruments for protein overexpression and purification 
 
 Overexpression clone of Escherichia coli (strain XL1-Blue MRF) containing 
NS2Bco-NS3pro fragment in pQE-30 vector was obtained from Prof. Padmanabhan 
(previously at the University Kansas, U.S.A). Isopropyl-β-D-thiogalactopyranoside 
(IPTG) was purchased from Calbiochem. Ni
2+
-nitrilotriacetic acid (NTA)-agarose resin 
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was from Qiagen (Chadworth, CA). Fluorogenic peptide subtrate Boc-Gly-Arg-Arg-
MCA was obtained from Peptide Institute, Inc. (Osaka, Japan). For column separation, 
Sephadex G-75 was supplied by Amersham Pharmacia and Hiload 16/60 Superdex 75 
preparative grade. Bio-Rad Protein Assay kit (Bio-Rad, U.S.A.) was used for 
determination of soluble protein concentration. Pre-stained SDS-PAGE standards (Low 
range) from BioRad and Mark12
TM
 Unstained Standard (Invitrogen Corp.) were used as 
standard in SDS-PAGE for protein molecular weight separation. 
 
 Sorvall GSA and Sorvall RC-5B refrigerated superspeed centrifuges were used 
for cell sedimentation. Tomy autoclave SS-325 was used for autoclaving solutions and 
glasswares. For protease bioassays, the Cary Eclipse Fluorescence spectrophotometer 
(Varians) was used to measure the intensity of the fluorogenic moiety (7-amino-4-
methylcourmarin, AMC) from the cleaved fluorogenic peptide substrate (excitation at 
385 nm and emission at 465 nm). Shidmadzu UV-Visible Recorder Spectrophotometer 
(UV-160) was used for optical density (OD) and quantitative protein assay.  
 
3.2.1.2 Media for bacterial cell growth 
 
Luria-Bertani (LB) agar  
Formulation: 0.5 g Yeast extracts, 1.0 g bacto-tryptone, 1.0 g NaCl, 1.5 g agar, 100 ml 
distilled water, 0.1 ml ampicillin (100 mg/ml). 
 
 The ingredients above were dissolved in 75 ml distilled water. The solution was 
adjusted to pH 7.0 and brought to a final volume of 100 ml. The medium was then 
sterilized by autoclaving for 20 minutes at 121
o
C. When the medium reached 45
o
C, it 
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was supplemented with ampicillin (working concentration of 100 µg/ml). 25 ml of the 
medium was poured into 4 LB plates. The plates were dried, wrapped and stored at 4
o
C. 
 
Luria-Bertani (LB) medium 
Formulation: 5 g Yeast extracts; 10 g bacto-tryptone; 10 g NaCl; 1000 ml distilled 
water; 1 ml ampicillin (100 mg/ml). 
 
 The ingredients above were dissolved in 900 ml distilled water. The solution 
was adjusted to pH 7.0 and brought to a final volume of 1000 ml. The medium was then 
sterilized by autoclaving for 20 minutes at 121
o
C. The medium was cooled to room 
temperature and supplemented with ampicillin (working concentration of 100 µg/ml). 
The medium was wrapped and stored at 4
o
C.  
 
3.2.1.3 Stock solutions 
 
Ampicillin stock solution (100 mg/ml) 
 The stock solution was prepared in deionised water and filtered through 0.22 μm 
pore size cellulose acetate membrane (Sartorius). The solution was then dispensed into 
aliquots of 1 ml and stored at 4
o
C. 
 
IPTG stock solution (0.5 M) 
 1.192 g of IPTG was dissolved in 10 ml deionised water (dH2O) and filtered. 
The solution was then dispensed into aliquots of 1 ml and stored at -70
o
C. 
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Imidazole stock solution (5 M) 
 3.40 g imidazole was dissolved in deionised water and made up to a volume of 
10 ml. 
 
3.2.1.4 Buffers for protein purification and dialysis 
 
Buffer A 100 mM Tris-HCl, 300 mM NaCl, pH 8.0 
Formulation: 2.42 g Tris; 3.51 g NaCl; 200 ml dH2O (deionised water). 
 
 The ingredients above were dissolved in 150 ml dH2O. The solution was 
adjusted to pH 8.0 with HCl and the volume was made up to 200 ml with dH2O. 
 
Buffer B 100 mM Tris-HCl, 300 mM NaCl, 6 M Urea, pH 8.0 
Formulation: 6.05 g Tris; 8.78 g NaCl; 180.18 g urea; 500 ml dH2O. 
 
 The ingredients above were dissolved in 450 ml dH2O. The solution was 
adjusted to pH 8.0 with HCl and the volume was made up to 500 ml with dH2O. 
 
Buffer C 100 mM Tris-HCl, 300 mM NaCl, 6 M Urea, pH 7.5 
Formulation: 2.42 g Tris; 3.51 g NaCl; 72.07 g urea; 200 ml dH2O (deionised water). 
 
 The ingredients above were dissolved in 150 ml dH2O. The solution was 
adjusted to pH 7.5 with HCl and the volume was made up to 200 ml with dH2O. 
 
Buffer D 100 mM Tris-HCl, 300 mM NaCl, pH 7.5 
Formulation: 12.1 g Tris; 17.55 g NaCl; 1000 ml dH2O. 
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 The ingredients above were dissolved in 900 ml dH2O. The solution was 
adjusted to pH 7.5 with HCl and the volume was made up to 1000 ml with dH2O. 
 
3.2.1.5 Solutions for Sodium Dodecyl Sulfate – Polyacrylamide Gel Electrophoresis 
(SDS-PAGE)  
 
30 % Acrylamide/ 0.8 % Bisacrylamide (w/w) solution  
Formulation: 60 g Acrylamide; 1.6 g N,N’-methylene bisacrylamide. 
 
 The acrylamide was firstly dissolved in 150 ml distilled water. Then, the 
bisacrylamide was added into the solution and mixed until dissolved. The solution was 
brought to a final volume of 200 ml, filtered and stored at 4
o
C in a tightly capped amber 
bottle. 
    
4X, 1.5 M Tris.Cl / 0.4 % SDS, pH 8.8  
Formulation: 91 g Tris base; 2 g SDS. 
 
 
 Tris was dissolved in 450 ml distilled water.  The solution was adjusted to pH 
8.8 with concentrated HCl and made up to a final volume of 500 ml with distilled water, 
filtered through a 0.45 μm filter and stored at 4oC.   
 
4X, 0.5 M Tris.Cl / 0.4 % SDS, pH 6.8 
Formulation: 6.05 g Tris base; 0.4 g SDS. 
 
  
 Tris was dissolved in 50 ml distilled water.  The solution was adjusted to pH 6.8 
with concentrated HCl and made up to a final volume of 100 ml with distilled water,
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 filtered through a 0.45 μm filter and stored at 4oC.   
 
10 % w/v Ammonium persulfate (APS) 
 0.1 g Ammonium persulphate was dissolved in 1 ml distilled water in a 1.5 ml 
eppendorf tube. The solution was freshly prepared prior to use. 
 
5X, Running buffer, SDS/ Electrophoresis buffer (concentrated stock) 
Formulation: 7.55 g Tris base; 36.0 g glycine; 2.5 g SDS; 500 ml distilled dH2O. 
 
 The ingredients above were mixed, stirred until dissolve and stored at 4
o
C. This 
concentrated stock solution was diluted to 1X, SDS/ electrophoresis running buffer 
prior to use. 
  
2X, SDS / sample loading buffer (concentrated stock) 
Formulation: 2.5 ml 4X, 0.5 M Tris.Cl / 0.4 % SDS, pH 6.8 ; 2.0 ml glycerol ; 0.4 g 
SDS; 0.2 ml -mercaptoethanol; 10.0 mg bromophenol blue. 
 
 The ingredients above were dissolved in distilled water and brought to a final 
volume of 10 ml. The sample dye solution was then aliquot into 1 ml volume size and 
stored at –70oC.  
 
Coomasie Blue staining solution 
Formulation: 50 % (v/v) Methanol; 0.05 % (w/v) Coomasie Brilliant Blue R-250; 10 % 
(v/v) acetic acid; 40 % distilled dH2O.  
 
 The Coomasie Brilliant Blue R-250 was dissolved in methanol before adding
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 acetic acid and water. The solution could be stored on open shelves at room 
temperature for six months. If precipitation occurred, the solution was filtered through 
Whatman filter paper to obtain a homogenous solution.  
 
Destaining solution 
Formulation: 7 % (v/v) Acetic acid; 5 % (v/v) methanol; 88 % (v/v) distilled dH2O. 
 
 The solution was prepared in volume size of 1 litre.   
 
Fixing solution 
Formulation: 50 % (v/v) Methanol; 10 % (v/v) acetic acid; 40 % (v/v) distilled dH2O. 
 
 The solution was prepared in volume size of 1 litre and could be stored on open 
shelves at room temperature for 1 month.    
 
Gel drying solution (Promega Gel Drying Kit) 
Formulation: 40 % (v/v) Methanol; 10 % (v/v) glycerol; 7.5 % (v/v) acetic acid; 42.5 % 
(v/v) distilled dH2O. 
 
 The solution was prepared in volume size of 100 ml, mixed well and stored on 
open shelves.   
 
3.2.1.6 12 % SDS-PAGE gel 
 
A. Separating gel solution  
Formulation: 6.00 ml 30 % Acrylamide/0.8 % bisacrylamide (w/w); 3.75 ml 4X, 1.5 M
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 Tris.Cl / 0.4% SDS, pH 8.8; 5.25 ml distilled dH2O; 50 μl 10 % APS; 10 μl N,N,N’,N’-
tetramethylethyldiamine (TEMED). 
 
 A glass-plate sandwich was assembled using two clean glass plates and two 0.75 
mm spacers, and was locked to a casting stand. The above ingredients were prepared in 
a 30 ml tube, swirled gently to mix properly. As soon as APS and TEMED were added 
and mixed properly, the solution was immediately poured into the pre-packed sandwich 
SDS-PAGE slab. Care was taken to avoid inclusion of bubbles. A layer of methanol 
(approximately 1 cm in height) was laid on top of the solution to compress the solution, 
ensuring an even separating gel formation. The gel was allowed to polymerize for 30 to 
60 minutes at room temperature. 
 
B. Stacking gel solution  
Formulation: 650 µl 30 % Acrylamide / 0.8 % bisacrylamide (w/w); 1.25 ml 4X, 1.5 M 
Tris.Cl / 0.4 % SDS, pH 6.8; 3.05 ml distilled dH2O; 25 μl 10 % APS; 5 μl TEMED. 
 
 The above ingredients were prepared in a 30 ml tube and swirled gently to mix 
properly.  The methanol layer on top of the separating gel was poured out.  The stacking 
solution was immediately poured into the sandwich gel slab, on top of the polymerized 
separating gel. A 0.75 mm Teflon comb was inserted into the layer of stacking gel 
solution. The stacking gel was allowed to polymerize for 30 to 45 minutes at room 
temperature. 
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3.2.1.7 Dialysis tubing preparation 
 
Formulation: 20 g Sodium bicarbonate; 2 ml 0.5 M ethylenediaminetetraacetic acid 
(EDTA); 1000 ml dH2O. 
 
 The ingredients above were mixed to form 2 % sodium bicarbonate / 1 mM 
EDTA (pH 8.0) solution. Dialysis tubing was cut into lengths of 18 to 24 inches and 
curled into a large volume of the above solution. The tubings were boiled for 10 
minutes, rinsed twice with distilled water, and boiled again for 10 minutes in a large 
volume of 1 mM EDTA (pH 8.0). The tubings were allowed to cool and stored at 4
o
C in 
a fresh solution of 1 mM EDTA (pH 8.0) in sterile distilled water (the tubings were 
submerged in the solution to enhance the storage condition).  The tubings were washed 
thoroughly inside and outside with distilled water prior to use. 
 
3.2.1.8 Precipitating buffers for crystallization trials 
 
 The following crystallization kits were used for crystallization screens: 
Crystal screen
TM
, Crystal screen 2
TM
 and PEG / Ion Screen
TM
 from Hampton Research, 
U.S.A; The Classics, The Pegs, The pHClear
TM
, The SM1
TM
, The AmSO4 and The 
MPDs from Nextal Biotech; Wizard
TM
 I and Wizard
TM
 II from Emerald Biosystems, 
U.S.A. 
The different formulations for each kit are listed in Appendix 1. 
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3.2.1.9 Cleaning and siliconizing cover slips  
 
 Microscope cover slips were repeatedly cleaned with detergent and rinsed with 
water. They were then dried in a drying cabinet. Siliconizing of the cover slips was 
carried out in a fume hood. A siliconizing solution (dimethyldicholrosilane solution; 
about 2 % in 1,1,1-tricholroethane) was poured into a small beaker and placed in a 
dessicator. The dried cover slips were placed into a glass plate and put on top of the 
beaker containing the siliconizing solution in the dessicator, which was then connected 
to a vacuum pump. The set-up was left under vacuum for about 30 minutes. The cover 
slips, coated with the siliconizing solution, were then cleaned with a fibre-free cloth, 
blown with blow dryer and stored in a dry container until used.    
 
3.2.2 Methods  
 
 The protocols used in this study in the attempts to crystallize the DEN-2 
protease are as illustrated in a flowchart in Figure 3.1. 
 
3.2.2.1 Starter scale culture and glycerol stock preparation 
 
A glycerol stock of Escherichia coli strain XL1-Blue MRF’ transformed with 
the 6x-His-NS2B-3pro expression plasmid was obtained through personal contact with 
Yusof et al. (2000). An inoculum was streaked across one side of an LB agar plate 
using sterile technique. This step was repeated across the surface of the plate and the 
plate was incubated at 37
o
C until colonies appear.   
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Figure 3.1 Flowchart of protocols involved in this study towards the crystallization 
trials of DEN-2 protease. 
 
Protein overexpression and 
harvesting 
Protein purification 
Protein extraction 
Protein crystallization 
screens 
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A single bacterial colony was isolated from an overnight LB agar plate and 
inoculated into a sterile culture tube containing 10 ml of LB broth. This procedure was 
repeated to yield several tubes of the bacterial mini-cultures.  The tubes were loosely 
capped and grown at 37
o
C for overnight in a shaker (Innova 4000 Incubator Shaker, 
New Brunswick Scientific). These stocks were used for larger scale culture and storage 
purposes.  For storage purpose, 2.5 ml sterilized glycerol was added to each of the 10 
ml culture (yielding a stock solution containing 20 % glycerol) and mixed well. One ml 
of the stock solution was aliquoted into 1.5 ml centrifuge tubes and stored at –70oC.      
 
3.2.2.2 Large scale protein overexpression, harvesting and extraction 
 
 Frozen glycerol stock was thawed on ice and 125 μl stock solution was 
transferred into an LB medium (50 ml) containing 100 µg/ml ampicillin. The culture 
was left to grow overnight at 37
o
C, shaking at 250 rpm.  
 
 After 1 day, 10 ml of the overnight culture was inoculated into each of 6 x 1 litre 
LB medium containing ampicillin (100 µg/ml). Starting OD600 (optical density at 600 
nm) of each medium was approximately 0.06. The cultures were incubated at 37
o
C, 
with shaking at 200 rpm until OD600 reached approximately 0.6. The bacterial cells 
were induced for protein expression by addition of IPTG (0.5 mM working 
concentration) for 3 hours. The cells were harvested by ultra-centrifugation at 6 000 
rpm (Sorvall RC-5B Refrigerated Superspeed centrifuge) for 15 minutes at 4
o
C, and the 
pellets obtained were stored at –70oC until used. 
 
 For protein extraction, the cell pellets were thawed on ice, resuspended in buffer 
A (100mM Tris.HCl, 300mM NaCl, pH 8.0) containing 1 mg/ml lysozyme and 
Protein Crystallization Attempts                                                                                                      Chapter 3 
   47 
incubated at 4
o
C for 30 minutes. The solution was then centrifuged at 15 800 rpm for 1 
hour at 4
o
C. The supernatant was discarded and pellet was again resuspended under 
denaturing condition with buffer B (6M Urea, 100mM Tris.HCl, 300mM NaCl, pH 8.0), 
followed by cell lysis with sonication on ice (9 x 10 sec), and the lysate was kept on ice 
for 1 hour. The lysate was clarified by centrifugation at 15 800 rpm for 1 hour at 4
o
C. 
The 6x-His-NS2B-3pro was predominantly soluble in the supernatant in its denatured 
form.  
 
3.2.2.3 Protein purification 
 
 The supernatant containing the soluble, denatured protein was filtered through a 
0.45 µm filter, batch-bound to 2 ml Ni
2+
-NTA (nickel-nitrilotriacetic acid) resin (pre-
equilibrated with buffer B) and incubated overnight at 4
o
C.  The resin was centrifuged 
briefly at 1000 x g, the unbound fraction collected, and the resin with bound protein was 
loaded onto a column (Bio-Rad; 1 x 3 cm). The column was washed extensively with 40 
ml of buffer B. Protein elution was done by loading 10 ml buffer C (6 M Urea, 100 mM 
Tris.HCl, 300 mM NaCl, pH 7.5) containing 500 mM imidazole. The eluted fractions 
were collected in 0.5 ml volume size and analysed with 12 % SDS-PAGE. The elution 
profile was monitored using the Bio-Rad protein assay kit. Peak fractions were then 
pooled and subjected to gel filtration chromatography. 
 
 The next step of protein purification involved two types of column used in gel 
filtration chromatography: preparative Sephadex
TM
 G-75 column and pre-packed Hiload 
Superdex
TM 
200 column. For the first type of column, a Bio-Rad column (50 cm x 1.5 
cm) was used and loaded with pre-treated Sephadex
TM
 G-75 (bed volume was 
approximately 81 cm
3
). Pre-treatment of the resin was done as follows: 5 g of 
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Sephadex
TM
 G-75 was soaked in 70 ml sterilized dH2O. After discarding the 
supernatant, the resin was then equilibrated twice with buffer B. Sodium azide was then 
added (end concentration of 0.02 %) to act as anti-microbial, and the slurry was 
carefully poured into the column and packed to remove air bubbles. 
 
 The pooled peak fractions from the previous batch purification on nickel column 
were slowly loaded into the gel filtration column and separated (at 4
o
C) under 
denaturing condition with buffer B at a constant flow rate of 1 ml min
-1
. Eluted fractions 
were collected in 1.5 ml volume size and analysed with 12 % SDS-PAGE. The elution 
profile was monitored using the Bio-Rad protein assay kit.  
 
Peak fractions with the desired molecular weight were pooled and diluted to less 
than 0.5 mg/ml in buffer B. Refolding of the denatured protein was performed by 
dialysis against four changes of buffer D (100 mM Tris.HCl, 300 mM NaCl, pH 7.5) for 
48 hours at 4
o
C. The dialysate was clarified by centrifugation (12 000 rpm for 1 hour) at 
4
o
C and concentrated using Vivaspin (MWCO 10 000) by centrifugation at 3000 x g for 
a few hours (Allegra X-12R centrifuge) until the volume was reduced to less than 2 ml. 
 
The refolded protein solution was then subjected to gel filtration 
chromatography (pre-packed Hiload Superdex
TM 
200 column) under native condition 
using buffer D to further purify the desired protease. The same separating conditions 
were used as previously described. The elution profile was monitored using the Bio-Rad 
protein assay kit and analysed with 12 % SDS-PAGE. Peak fractions of the purified 
protein were pooled and concentrated using Vivaspin by centrifugation until the 
concentration reached approximately 10 mg/ml. 
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 3.2.2.4 Bio-Rad Protein assay 
 
 The Bio-Rad Protein assay, based on method of Bradford, is a simple and 
accurate procedure for determining concentration of solubilized protein. The dye 
reagent was prepared by diluting 1 part of the Dye Reagent Concentrate with 4 parts 
distilled dH2O and filtered through Whatman #1 filter to remove particulates. Fifty 
microlitre of the protein solution was mixed with 2.5 ml of the diluted reagent, vortexed 
and incubated at room temperature for at least 5 minutes. Absorbance was measured at 
595 nm. The concentration of protein after purification was estimated from the bovine 
serum albumin (BSA) standard curve.  
  
3.2.2.5 Bovine serum albumin (BSA) standard curve 
 
 A stock of BSA solution with concentration 1 mg/ml was prepared in distilled 
dH2O. Standard solutions of BSA ranging from 0.2 to 0.9 mg/ml
 
were then prepared to 
construct a standard curve of absorbance at 595 nm.  
 
 
3.2.2.6 7-Amino-4-methylcoumarin (AMC) standard plot for protein assay 
 
 An AMC standard plot was used in the determination of the NS2B-NS3 protease 
activity. A working stock of AMC with concentration 10 M was prepared and standard 
AMC solutions ranging from 0 to 5.0 M were made up. 
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3.2.2.7 Preparation of fluorogenic peptide substrate 
 
 Fluorogenic substrate, BOC-Gly-Arg-arg-MCA, (5.4 mg) was dissolved in 830 
l DMSO to furnish a concentrated stock solution of 10 mM. This stock was further 
diluted to 1 mM and 2.5 mM stock solutions. All the prepared stock solutions were 
stored at –70oC in the dark to prolong the substrate stability.      
 
3.2.2.8 Determination of protease kinetic properties 
 
 Protease activity (kinetic properties) was determined after its purification to 
ensure that the protease that goes through crystallization screens has activity. Protocols 
for protease assay follows those of Yusof et al. (2000)  and Teoh (2004). 
 
The reaction mixture constituted of a constant concentration of 1 μM of 
protease, substrate concentrations between 20 to 200 μM and Tris buffer. The end 
volume of each mixture was 200 μl. The activity of the protease complex was 
characterized by the fluorogenic substrate, which released the fluorogenic moiety (7-
amino-4-methyl coumarin, AMC) upon cleavage by the active protease. The assays 
were incubated at 37
o
C for 30 minutes. Measurement of the intensity of the released 
AMC was detected with Cary Eclipse Fluorescence spectrophotometer (Varians) at 
excitation wavelength of 385 nm and emission wavelength of 465 nm.  The control (in 
the absent of substrate) and reaction assays were done in triplicate.   
 
3.2.2.9 Crystallization screens 
 
  Most of the crystallization trials were carried out at the Department of Molecular
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Biology and Biotechnology, the University of Sheffield, under the supervision of Prof. 
Dr. David Rice. In this study, the vapour-diffusion methods were employed in the 
crystallization trials involving the hanging drop and sitting drop methods. Formulations 
of the precipitating buffers are listed in Appendix 1. The concentration of the protein 
solution used in the screens was about 10 mg/ml. The protein solution was centrifuged 
at 13 000 rpm for 2 minutes to settle down any precipitant that might be present.  
 
3.2.2.9(a) Hanging drop method 
 
 The hanging drop method was carried out manually using 24-well Linbro plates 
(Hampton Research, USA) (Figure 3.2a). An oil sealant ring was put around each well 
which was then filled with and 500 μl of the precipitating buffers. The protein solution 
was dropped onto a siliconized cover slip and an amount of the precipitating buffer 
from the well was added to it in the following volumes: 
      1 μl protein solution + 1 μl precipitating buffer; or 
      2 μl protein solution + 2 μl precipitating buffer. 
 
 The cover slip was then inverted over the well containing the precipitating 
buffer such that the drop hanged from its underside. Care was taken to ensure that the 
well was properly sealed to ensure that the drop gradually become dehydrated and 
equilibrated with the solution in the reservoir. This procedure was repeated for all the 
precipitating conditions. The plates were then incubated at 17
o
C. The screens were 
monitored for any crystal formation by observation under the microscope.
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Figure 3.2 Diagram showing (a) a 24-well Linbro plate containing protein drops in 
sealed environment in the hanging drop method, and (b) the robotic system, The Hydra 
II-Plus-One System, available at the Department of Molecular Biology and 
Biotechnology, The University of Sheffield, used in the sitting drop method. 
(a) 
(b) 
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3.2.2.9(b) Sitting drop method 
 
 The sitting drop technique was performed by employing the automated 
system using the Hydra II-Plus-One System (Figure 3.2b). A drop of 0.2 µl protein 
solution and 0.2 µl precipitant was placed on each drop support of a 96 well 
Crystalquick plate (Greiner Bio-one, Starlab GMBH, Germany). Each reservoir 
contained 100 µl of precipitating buffer. The plate was sealed with microplate sealing 
film (Starseal Advanced Polyefin film, Starlab GMBH, Germany) and incubated at 
17
o
C. The screens were monitored for any crystal formation by observation under the 
microscope. 
 
3.3 Results 
3.3.1 Expression and purification of active DEN-2 NS2B-NS3pro 
 
 The cultures of competent Escherichia coli strain XL1-Blue MRF’ transformed 
with the 6x-His-NS2B-NS3pro expression plasmid was obtained from Prof. Rohana 
Yusof, Department of Molecular Medicine, University of Malaya (personal 
communication). To express the DEN-2 protease complex, similar strategy, with minor 
modifications, as described by Yusof et al. (2000), was employed. Large scale 
overexpression of protein was performed to yield sufficient amount of purified protein 
for crystallization screens. Since the protein precursor was associated with insoluble 
inclusion bodies, it was solubilized from the insoluble pellet fraction of the bacterial cell 
lysate using a buffer containing urea (buffer B). 
 
 The protein precursor was put through several steps of purification. Firstly, 
purification was done using Ni
2+
 affinity column (as described in section 3.2.2.3). The
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elution profile is as shown on Figure 3.3. The precursor was eluted with 500 mM 
imidazole (Figure 3.4, lane 3). The concentration of imidazole used seemed to be high, 
which may explain the co-elution of other proteins with lower molecular weight 
observed. Hence, gradient elution of the protein precursor was done using increasing 
concentrations of imidazole in the elution buffer to obtain cleaner protein precursor. 
From Figure 3.5, the precursor was observed to be eluted out of the solution with 
imidazole concentration as low as 2 mM. However, when the eluted protein solution 
was subsequently dialysed, the protein precursor did not refold into its native 
conformation. This is shown in Figure 3.6, lanes 4, 5 and 6. Consequently, buffer C 
containing 500 mM imidazole was still used to elute the protein precursor out of the 
Ni
2+
 affinity column.  
 
 The second purification step involved the use of size exclusion gel 
chromatography (as described in section 3.2.2.3). Initially, preparative Sephadex
TM
 G-
75 was used (Figure 3.7). Later on, however, purification was done on pre-packed 
Hiload Superdex
TM
 200 column, since this column resulted in better separation of 
proteins under denaturating condition (Figure 3.8). Fractions 11 to 14, contained the 
purified NS2Bco-NS3pro and thus were pooled together. The protein refolded into its 
active conformation when subjected to dialysis under native condition (Figure 3.4, lane 
6). Unfortunately, as soon as the active conformation was obtained, auto-cleavage took 
place, releasing NS2B (~ 8 kDa), NS3pro (~ 23 kDa) and other degenerative products. 
 
 The following purification step involved passing the dialysate through the pre-
packed Hiload Superdex
TM
 200 column under native conditions. As shown in Figure 
3.9, two peaks were observed in the polarograph, each representing the refolded 
protease. The peak on the right represented fractions which contained the active
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Figure 3.3 Elution profile of fractions obtained from purification of DEN-2 protease 
precursor on Nickel (Ni
2+
) affinity column. Absorbance was measured at wavelength of 
595 nm. Fractions 2 and 3 were further purified on gel filtration column. 
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Figure 3.4 Expression and purification profile of NS2B-NS3pro illustrated by 
separation using 12 % SDS-PAGE and stained using coomassie blue. 
Lane 1: Protein molecular weight marker 
Lane 2: Soluble bacterial proteins after expression induced with IPTG  
Lane 3: Fraction from Ni
2+
-NTA affinity column eluted with 500 mM imidazole 
Lane 4: Non-binding fraction on Ni
2+
-NTA resin  
Lane 5: Fraction from gel filtration column under denaturing condition using 
  Hiload 16/60 Superdex 75 preparative grade 
Lane 6: After dialysis, refolded protein precursor which underwent cleavage to 
  generate NS2B (~ 8 kDa) and NS3pro (~ 23 kDa)  
Lane 7: Protein molecular weight marker 
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Figure 3.5 Profile of gradient elution of NS2B-NS3pro using different 
concentrations of imidazole as illustrated by 12 % SDS-PAGE. 
Lane 1:   Protein molecular weight marker 
Lane 2:  Non-binding fraction 
Lane 3:   Wash 
Lane 4:   0.2 mM imidazole 
Lane 5:   0.2 mM imidazole 
Lane 6:  0.2 mM imidazole 
Lane 7:  0.5 mM imidazole 
Lane 8:   0.5 mM imidazole 
Lane 9:   0.5 mM imidazole 
Lane 10:  1 mM imidazole  
Lane 11: 1 mM imidazole 
Lane 12: 1 mM imidazole 
Lane 13: 2 mM imidazole 
Lane 14: 2 mM imidazole 
Lane 15: 2 mM imidazole 
Lane 16: Protein molecular weight marker  
Lane 17: 3 mM imidazole 
Lane 18: 3 mM imidazole 
Lane 19: 3 mM imidazole 
Lane 20: 4 mM imidazole 
Lane 21: 4 mM imidazole 
Lane 22: 4 mM imidazole 
Lane 23: 5 mM imidazole 
Lane 24: 5 mM imidazole 
Lane 25: 5 mM imidazole 
Lane 26: 20 mM imidazole 
Lane 27: 20 mM imidazole  
Lane 28: 20 mM imidazole 
Lane 29: 50 mM imidazole 
Lane 30: 50 mM imidazole 
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Figure 3.6 Profile of protein solution eluted from Ni
2+
 affinity column and dialysis 
products illustrated by 12 % SDS-PAGE. 
 
 
Lane 1: Protein molecular weight marker 
Lane 2: Ni
2+
 affinity column (elution with 20 mM imidazole) 
Lane 3: Gel filtration (denatured) 
Lane 4: First dialysis (soluble fraction) 
Lane 5: Second dialysis (pellet) 
Lane 6: Second dialysis (soluble fraction) 
Lane 7: Protein molecular weight marker 
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Figure 3.7 Elution profiles of eluents from size exclusion chromatography column 
using preparative Sephadex
TM
 G-75 (under denaturing condition and after subjected to 
Ni
2+
 affinity column). (a) Plot of protein concentration of the purified fractions 
(absorbance measured at 595 nm), and (b) 12 % SDS-PAGE showing fractions 
containing NS2Bco-NS3pro.  
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Figure 3.8 Elution profiles of eluents from size exclusion chromatography column 
using pre-packed Hiload Superdex
TM
 200 column (under denaturing condition and after 
subjected to Ni
2+
 affinity column). (a) Plot of protein concentration of the purified 
fractions (absorbance measured at 595 nm), and (b) 12 % SDS-PAGE showing fractions 
containing NS2Bco-NS3pro.              
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Figure 3.9 Elution profiles of eluents from size exclusion chromatography column 
using pre-packed Hiload Superdex
TM
 200 column (under native condition). (a) Plot of 
protein concentration of the purified fractions (absorbance measured at 595 nm), and (b) 
12 % SDS-PAGE of the purified fractions. 
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protease and its degenerative products. The peak on the left contained a less pure 
fraction, even though the presence of NS2B and NS3pro is observed, as shown by the 
SDS-PAGE in Figure 3.9b. Concentration of each fraction 29 to 35 was determined 
using Bio-Rad protein assay. Figure 3.10 shows the Bovine serum albumin standard 
curve used in the determination of protein concentrations in the fractions. Table 3.1 
shows the protein yield after each purification step and the final overall protein yield.  
 
3.3.2 Kinetic properties of DEN-2 NS2B-NS3pro 
 
 Biochemical properties, such as the type of buffers, optimum pH, and ionic 
strength greatly affect enzyme activities. The biochemical properties for performing in 
vitro assays of DEN-2 NS2B-NS3pro have been determined in previous studies 
(Hadinur, 2005; Teoh, 2004; Yusof et al., 2000). In this study, kinetic properties of the 
protease were determined to ensure that the protease, which was subsequently put 
through crystallization trials, was active. Based on the report by Yusof et al. (2000), the 
fluorogenic substrate, BOC-Gly-Arg-Arg-MCA, was used in this study. The cleavage of 
this substrate by the protease follows the Michaelis-Menten kinetics, and is dependent 
upon the incubation time and substrate concentration. 
 
 The amount of AMC released into the assay solution (in terms of intensity) upon 
cleavage of the substrate by the protease was determined from an AMC standard curve 
(Figure 3.11). A Lineweaver-burk plot, 1/V (the reciprocal of velocity), versus 1/[S], 
the reciprocal of substrate concentration, was plotted and found to be linear (Figure 
3.12). Table 3.2 illustrates the different kinetic properties of DEN-2 NS2B-NS3pro 
obtained from this study. Each of the fractions was then concentrated down to about 10 
mg/ml for crystallization screen.  
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Figure 3.10 The Bovine serum albumin (BSA) standard curve. The linear range of 
the assay for BSA is 0.2 to 0.9 mg/ml.   This plot was prepared and used to calculate the 
DEN-2 NS2B-NS3 protease complex concentration. 
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Table 3.1 Table showing protein yield after each step of purification and the 
overall protein yield. 
 
 
 
 
 
 
Technique acquired Substance Amount (weight) Yield 
 
1. 
 
 
Overexpression & harvesting 
 
 
Pellet 
 
5000 mg 
 
 
2. 
 
Extraction (lysis) Total protein 397.97 mg 
3. 
 
Immobilized metal (Ni
2+
)  
affinity column 
 
Purified protein 19.12 mg 
4. 
 
Gel filtration chromatography 
(denatured) 
 
Protein loaded 16.75 mg (2 ml) 
Purified protein 8.09 mg 
5. 
 
 Dialysis Protein 5.48 mg 
6. 
 
Gel filtration chromatography 
(native) 
 
Protein loaded 4.83 mg (400 μl) 
Purified protein 2.28 mg 
Overall yield 0.74% 
 
4.80% 
 
 
 
48.30% 
67.73% 
 
 
47.20% 
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Figure 3.11 The 7-amino-4-methylcoumarin (AMC) standard curve. The AMC   
concentrations assayed range from 0.0 to 5.0 M.  Data are reported as mean  standard 
deviation. This plot directly indicates the amount of AMC released into the assay 
solution, and hence, was used to characterize the NS2B-NS3pro kinetic properties. The 
standard curve assay was done in triplicate. 
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Figure 3.12 The Lineweaver-Burk plot for DEN-2 NS2B-NS3pro. The protease 
complex kinetic properties were determined from assays which consisted of the 
fluorogenic substrate (concentration ranging from 25 to 200 M), protease 
concentration at 1 M and buffer.  Data are reported as mean  standard deviation. 
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Table 3.2.  Kinetic properties of NS2B-NS3pro.  
 
 
The kinetic properties were charaterized using the fluorogenic substrate, BOC-Gly-Arg-
Arg-MCA, as described earlier (section 3.2.2.8). The maximum velocity, Vmax, is the 
maximum number of reactions per unit time catalysed by one mole of protease (Garrett 
and Grisham, 1997a). The Michaelis constant, Km, is defined as the substrate 
concentration at which velocity equals half the maximal velocity. The turnover number 
of the protease, kcat, is a measure of the protease’s catalytic activity. kcat is defined as the 
number of substrate molecules converted to the product per protease molecule per unit 
time when the protease is saturated with substrate. kcat/Km is a measure of the catalytic 
efficiency of the protease operating at substrate concentrations substantially below 
saturation amounts. (See Appendix 2 for calculation methods). 
 
 
 
 
Vmax Km kcat kcat/Km 
 
0.16 M min-1 
 
113.21 M 
 
0.0027 sec
-1
 
 
23.85 M
-1
sec
-1 
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3.3.3 Crystallization screens of DEN-2 NS2B-NS3pro 
 
 A total of 818 crystallization buffers were used in the crystallization screens of 
the DEN-2 NS2B-NS3pro. Crystallization attempts did not result in successful crystal 
formation. Upon incubation at 17
o
C with the precipitating buffers, the protein solutions 
either formed clear solutions, precipitates or phase separation (Figure 3.13).  
 
3.4 Discussion 
 
 In this chapter, we report the overexpression of DEN-2 protease complex in 
Escherichia coli, its purification and kinetic properties determination. Methods 
employed followed those reported by Yusof et al. (2000), with some optimization to 
ensure the protein yielded is of high purity and suitable for crystallization trials. The 
yield of the purified protease complex was considerably low at 0.74 % (Table 3.1). It 
was found, at the later stage of the study, that the low yield was due to the bacterial 
clone hosting the protein precursor losing its viability as a result of technical difficulties 
in the storage of the glycerol stocks. 
 
 The kinetic properties of the enzyme (Table 3.2) were found to be relatively 
poor compared to those reported by Yusof et al. (2000) where the values reported were 
0.031 s
-1
 (kcat), 180 μM (Km) and 172 s
-1
 M
-1
 (kcat/Km). On the other hand, one 
dimensional profile of the purified protease via SDS-PAGE (Figure 3.4) illustrated the 
enzyme complex to be highly active upon purification which, after dialysis, refolded 
into its active conformation and underwent auto-cleavage to generate individual NS2B 
and NS3pro domains. This would signify that the recognition site (dibasic amino acids 
on the NS2B/NS3 junction) for binding to the active site of the protease was able to
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Figure 3.13 Pictures showing examples of the different forms of precipitates 
developed in the crystallisation screens of DEN-2 NS2B-NS3pro. 
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form interactions with the binding site for the cleaving process to proceed. This 
observation is substantial enough to allow the purified protease to be put through 
crystallization trials.  
 
 To check for possibility of mutation occurring, the plasmid carrying the DNA, 
which coded for the protease complex, was sent for sequencing. Figure 3.14a shows the 
translated amino acid sequences of NS2B-NS3pro from the DNA sequencing 
experiment. N-terminal amino acid sequencing was also performed on the purified 
protease complex (Figure 3.14b). The amino acid sequences shown in Figure 3.14 were 
exactly the same as those observed for the protease complex reported by Yusof et al. 
(2000). From Figure 3.14b, it can be seen that the active protease cleaved the 
NS2B/NS3 junction. In addition, the active protease is seen to cleave within the NS3 
domain, where it recognized the basic arginine residue (R is underscored in Figure 
3.14b), resulting in a band on the SDS-PAGE corresponding to protein with molecular 
weight 17 kDa. This finding is in agreement to that reported by Krishna Murthy et al. 
(1999) where they observed that from solvent accessibility calculations, NS3pro 
appeared to be in a partially “open” conformation. Here, the catalytic triad & residues in 
the substrate binding pocket were accessible to model substrates, thus allowing some 
level of intrinsic activity. 
 
 Crystallization experiments performed in this study, however, did not 
successfully lead to protein crystal formations. There was an instance where crystals 
were obtained (data not shown) using PEG/Ion Screen
TM
 #1 (refer Appendix 1). These 
crystals were observed as orthorhombic prisms and hexagonal plates. However, the 
diffraction patterns of the electron clouds obtained after the crystals were mounted on 
the single beam x-ray diffractometer (Rigaku Ru 2000 rotating anode, Rigaku/MSC,
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Figure 3.14 (a) Translated amino acid sequences of NS2B-NS3pro as a result of 
DNA sequencing experiment carried out on the plasmid carrying the DNA coding for 
the protease complex. The sequencing was done by Lark Technologies, Inc., Essex, UK. 
The sequences in blue colour represent the NS2B domain, while those in pink represent 
the NS3pro domain. It can be seen that there are six histidine residues on the N-
terminus of NS2B which serve as a tagging to facilitate the protein purification using 
immobilized metal-affinity chromatography (refer section 3.2.2.3). (b) Results from N-
terminal protein sequencing of the purified protein after dialysis (refolded into its active 
conformation). Sequencing was done at the Department of Molecular Biology and 
Biotechnology, the University of Sheffield. The different sets of sequences were 
matched to the SDS-PAGE profile of the purified protease according to the weight, as 
shown in parenthesis. 
3'5' Frame 3 
XXXXXXGXPXNXIXXXPXXXXWGKXXEXXXGKXXGXXXCPXXXWXFXFPRXXGGQXGXQ
XXQKGNXXXPEFETXTXXFFQXXXXFXGVXXXXXKTXXXDFLXXKQXRGFRXTFXXKXPXD
X–KTXFYXXLIXLNIGVSRGPFXFXXRNHKNLFPLXADNNFTQNSLKRRXLTMRGSHHHHH 
HGSSADLELERAADVKWEDQAEISGSSPILSITISEDGSMSIKNEEEEQTLWYLWEVKKQR
AGVLWDVPSPPPVGKAELEDGAYRIKQKGILGYSQIGAGVYKEGTFHTMWHVTRGAVLM
HKGKRIEPSWADVKKDLISYGGGWKLEGEWKEGEEVQVLALEPGKNPRAVQTKPGLFKT
NAGTIGAVSLDFSPGTSGSPIIDKKGKVVGLYGNGVVTRSGAYVSAIAQTEKSIEDNPEIED
DIFRKKLN–LSLDSC– –IQ– –QNSXGFFRTLGCAG 
NS3(pro) 
AGVLWDVPSPPPVGKAELEDGAYRIKQKGILGYSQIGAGVYKEGTFHTMWHVTRGAVLMHKGKRIEP
SWADVKKDLISYGGGWKLEGEWKEGEEVQVLALEPGKNPRAVQTKPGLFKTNAGTIGAVSLDFSPG
TSGSPIIDKKGKVVGLYGNGVVTRSGAYVSAIAQTEKSIEDNPEIEDDIFRK (20 kDa) 
 
AGVLWDVPSPPPVGKAELEDGAYRIKQKGILGYSQIGAGVYKEGTFHTMWHVTRGAVLMHKGKRIEP
SWADVKKDLISYGGGWKLEGEWKEGEEVQVLALEPGKNPRAVQTKPGLFKTNAGTIGAVSLDFSPG
TSGSPIIDKKGKVVGLYGNGVVTR (17 kDa) 
 
6H-NS2B  
GSHHHHHHGSSADLELERAADVKWEDQAEISGSSPILSITISEDGSMSIKNEEEEQTLWYLWEVKKQR 
(8 kDa) 
(b) 
(a) 
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TX, U.S.A., with MAR345 Image Plate Detector) confirmed the crystals to be the salts 
of the precipitating buffer, and not of the purified protease. 
  
 Ironically, after all our attempts to crystallize the protease complex went futile 
and a homology model of the protease (not reported in this thesis) was generated for the 
next part of the study, a crystal structure data for the DEN-2 NS2B-NS3 protease 
complex was deposited into the protein data bank (PDB) (D'Arcy et al., 2006; Erbel et 
al., 2006). D’Arcy and co-workers genetically engineered the protease expression 
construct to make a 47-amino-acid hydrophilic core sequence assembly of NS2B 
(amino acids 1394–1440) linked via a nine-amino-acid linker (G4-S-G4) to the N-
terminal 185 amino acids of NS3 (amino acids 1476–1660). This construct led to the 
overexpression of a highly soluble protease complex which was then concentrated to the 
very high concentration of 60 to 80 mg/ml for crystallization trials. This expressed 
protease also did not undergo autocleavage upon folding to its active conformation due 
to the removal of the dibasic amino acids upstream of the NS2B/NS3 junction (by 
replacing the 10 amino acids upstream the N-terminal of NS3 with the linker). 
 
 In our study, one of the problems encountered was due to a highly dynamic 
protease that underwent autocleavage as soon as it resumed its active conformation. 
This led to a non-homogenous solution, a highly unfavourable condition for protein 
crystal formation. In addition, the protease complex was not so soluble in buffer. 
Concentration beyond 10 mg/ml resulted in precipitation. Replacement of the 10 amino 
acids upstream the N-terminal of NS3 (Figure 3.14; these amino acids are coded in dark 
blue) with the linker, as reported by the Novartis team, had resolved the solubility 
problem, thus their success in the crystallization trials. 
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3.5 Conclusion 
 
 In this study, the methods for purification of DEN-2 NS2B-NS3 protease in an 
attempt to obtain pure protein solutions suitable for crystallization screens were 
optimized. However, crystallization trials did not result in any protein crystal formation. 
The reasons for this were, firstly, the protease was not highly soluble in buffer and, 
secondly, the protease was highly dynamic and underwent autocleavage at NS2B/NS3 
junction as soon as it folded into its active conformation. Hence, crystallization trials 
were not successful due to purity problem (high degree of purity is required to obtain 
any initial hits) and homogeneity problem of the protein solution, where other 
degenerative products were present in the solution due to the cleaving process.  
 
 Subsequently, for projects on molecular modelling in this study of DEN-2 
protease, the model built from crystal data deposited into the PDB (PDBid: 2FOM) by 
Erbel et al. (2006) was used as the target. 
 
 
 
      
 
  
 
